Dogwood Therapeutics regains Nasdaq compliance; phase 2a Long-COVID data expected mid-Nov

Dogwood Therapeutics, Inc.

Regained Nasdaq minimum bid price compliance; closing bid price >= $1.00 for 10 consecutive trading days.
Top-line results from phase 2a study of IMC-2 for Long-COVID expected mid-November 2024.
Integration of Pharmagesic (Holdings) Inc. acquisition (closed early Oct 2024) ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.